MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been found in some cases diagnosed as seronegative neuromyelitis optica spectrum disorder (NMOSD). MOG-IgG allowed the identification of a subgroup with a clinical course distinct from that of NMOSD patients who are seropositive for aquaporin-4-IgG antibodies. MOG-IgG is associated with a wider clinical phenotype, not limited to NMOSD, with the majority of cases presenting with optic neuritis (ON), encephalitis with brain demyelinating lesions, and/or myelitis. Therefore, we propose the term MOG-IgG-associated Optic Neuritis, Encephalitis, and Myelitis (MONEM). Depending on the clinical characteristics, these patients may currently be diagnosed with NMOSD, acute disseminated encephalomyelitis, pediatric multiple sclerosis, transverse myelitis, or ON. With specific cell-based assays, MOG-IgG is emerging as a potential biomarker of inflammatory disorders of the central nervous system. We review the growing body of evidence on MONEM, focusing on its clinical aspects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649 · cited 2×
“Similarly, some MOGIgG-seropositive/AQP4-IgG-seronegative patients diagnosed with NMO do not fulfill the newly revised diagnostic criteria for NMOSD (1).”
BackgroundSelf-citationA serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Self-citationDistinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype
Kitley, J., Woodhall, M., Waters, P., Leite, M. I., Devenney, E., Craig, J., Palace, J., & Vincent, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31826aac4e · Cited by 445
Ramanathan, S., Prelog, K., Barnes, E. H., Tantsis, E. M., Reddel, S. W., Henderson, A. P., Vucic, S., Gorman, M. P., Benson, L. A., Alper, G., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515593406 · Cited by 384
Demographic and clinical features of neuromyelitis optica: A review
Pandit, L., Asgari, N., Apiwattanakul, M., Palace, J., Paul, F., Leite, M., Kleiter, I., Chitnis, T., & the GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515572406 · Cited by 341
Bettelli, E., Baeten, D., Jäger, A., Sobel, R. A., & Kuchroo, V. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28334 · Cited by 336 · cited 1×
“Notably, double-transgenic mice with both MOG-specific T cell receptors and an MOG-specific immunoglobulin heavy chain present more severe experimental autoimmune encephalitis than single transgenic mice, revealing that T cell/B cell cooperation is a key aspect in the pathogenesis of CNS autoimmunity (32, 33).”
BackgroundIglesias, A., Bauer, J., Litzenburger, T., Schubart, A., & Linington, C. (2001) · Glia · doi:10.1002/glia.1111 · Cited by 280
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.141 · Cited by 262
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Kim, S.-M., Woodhall, M. R., Kim, J.-S., Kim, S.-J., Park, K. S., Vincent, A., Lee, K.-W., & Waters, P. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000163 · Cited by 232
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
Hacohen, Y., Absoud, M., Deiva, K., Hemingway, C., Nytrova, P., Woodhall, M., Palace, J., Wassmer, E., Tardieu, M., Vincent, A., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000081 · Cited by 230
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Zekeridou, A., & Lennon, V. A. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000110 · Cited by 203
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis
Rostasy, K., Mader, S., Schanda, K., Huppke, P., Gärtner, J., Kraus, V., Karenfort, M., Tibussek, D., Blaschek, A., Bajer-Kornek, B., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2956 · Cited by 182
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies
Kaneko, K., Sato, D. K., Nakashima, I., Nishiyama, S., Tanaka, S., Marignier, R., Hyun, J.-W., Oliveira, L. M. D., Reindl, M., Seifert-Held, T., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312676 · Cited by 106 · cited 8×
“Many MS therapies may actually exacerbate AQP4-IgG-seropositive NMOSD, as has been reported for betainterferons (87, 88), natalizumab (89, 90), and fingolimod (91, 92).”
ResultInfluentialSelf-citationAutoantibody to MOG suggests two distinct clinical subtypes of NMOSD
Yan, Y., Li, Y., Fu, Y., Yang, L., Su, L., Shi, K., Li, M., Liu, Q., Borazanci, A., Liu, Y., et al. (2016) · Science China Life Sciences · doi:10.1007/s11427-015-4997-y · Cited by 63
Sakuma, H. (2004) · Brain · doi:10.1093/brain/awh260 · Cited by 59
Cited by
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Lin, T.-Y., Chien, C., Lu, A., Paul, F., & Zimmermann, H. G. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1982697 · Cited by 16
Metadata
- Authors
- dos Passos, G. R., Oliveira, L. M., da Costa, B. K., Apostolos-Pereira, S. L., Callegaro, D., Fujihara, K., & Sato, D. K.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2018-04-04
- Volume
- 9
- Pages
- 217-217
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2795622288
- Cited by
- 200
- References
- 18
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.